Roger N Pearse
Overview
Explore the profile of Roger N Pearse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saldarriaga M, Darwiche W, Jayabalan D, Monge J, Rosenbaum C, Pearse R, et al.
Front Oncol
. 2022 Nov;
12:1020011.
PMID: 36387095
Recent insight in the genomic landscape of newly diagnosed multiple myeloma (NDMM) and its precursor conditions, monoclonal gammopathy of uncertain significance (MGUS), and smoldering myeloma have allowed the identification of...
2.
Hultcrantz M, Richter J, Rosenbaum C, Patel D, Smith E, Korde N, et al.
Blood Cancer Discov
. 2021 Oct;
1(3):234-243.
PMID: 34651141
Significance: Patients with multiple myeloma are immunocompromised, raising the question whether they are at higher risk of severe COVID-19 disease. In this large case series on COVID-19 in patients with...
3.
Forsberg P, Rossi A, Boyer A, Pearse R, Pekle K, Jayabalan D, et al.
Am J Hematol
. 2021 Aug;
96(12):1554-1562.
PMID: 34424561
Combination treatment regimens including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and a corticosteroid are standards of care for initial treatment of multiple myeloma (MM). We aimed to evaluate...
4.
Braunstein M, Petrova-Drus K, Rosenbaum C, Jayabalan D, Rossi A, Salvatore S, et al.
Am J Clin Pathol
. 2020 Jul;
154(6):767-775.
PMID: 32705137
Objectives: Crystal-storing histiocytosis (CSH) is rare in plasma cell dyscrasias, with only 3 cases reported in the setting of amyloid. No cases of crystal-negative histiocytosis coincident with multiple myeloma and...
5.
Hultcrantz M, Richter J, Rosenbaum C, Patel D, Smith E, Korde N, et al.
medRxiv
. 2020 Jun;
PMID: 32577667
Importance: New York City is a global epicenter for the SARS-CoV-2 outbreak with a significant number of individuals infected by the virus. Patients with multiple myeloma have a compromised immune...
6.
7.
Gomez-Arteaga A, Mark T, Guarneri D, Christos P, Gergis U, Greenberg J, et al.
Bone Marrow Transplant
. 2019 Jun;
54(12):2027-2038.
PMID: 31190006
High-dose melphalan (MEL200) followed by autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma (MM). Bendamustine induces responses in MM resistant to other alkylators. Our prior...
8.
Mark T, Forsberg P, Rossi A, Pearse R, Pekle K, Perry A, et al.
Blood Adv
. 2019 Feb;
3(4):603-611.
PMID: 30792190
The addition of clarithromycin enhances the efficacy of lenalidomide plus dexamethasone in treatment-naive multiple myeloma (MM). We conducted a phase 2 trial to evaluate the safety and efficacy of clarithromycin,...
9.
Forsberg P, Rossi A, Boyer A, Tegnestam L, Pearse R, Perry A, et al.
Am J Hematol
. 2019 Feb;
94(5):539-545.
PMID: 30740766
Carfilzomib and dexamethasone (Kd) has significant activity in relapsed and refractory multiple myeloma. Kd has not previously been evaluated in newly diagnosed multiple myeloma (NDMM). We report a single-arm phase...
10.
Reich-Slotky R, Makhani S, Vasovic L, Pearse R, Rossi A, Philips A, et al.
Leuk Lymphoma
. 2018 May;
59(12):2829-2835.
PMID: 29790808
Washing cryopreserved peripheral blood stem cell (PBSC) products can decrease infusion-related adverse reactions but can also result in cell loss and reduced cell viability. To assess the risk and benefit...